Retisert Bausch & Lomb/control delivery systems

Lyndell L. Lim, Justine R. Smith, James (Jim) Rosenbaum

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Retisert (Envision TD), a sustained release intraocular implant containing fluocinolone acetonide, has been developed and launched in the US by Bausch & Lomb and Control Delivery Systems for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Original languageEnglish (US)
Pages (from-to)1159-1167
Number of pages9
JournalCurrent Opinion in Investigational Drugs
Volume6
Issue number11
StatePublished - Nov 2005

Fingerprint

Fluocinolone Acetonide
Posterior Eye Segment
Uveitis

ASJC Scopus subject areas

  • Pharmacology

Cite this

Retisert Bausch & Lomb/control delivery systems. / Lim, Lyndell L.; Smith, Justine R.; Rosenbaum, James (Jim).

In: Current Opinion in Investigational Drugs, Vol. 6, No. 11, 11.2005, p. 1159-1167.

Research output: Contribution to journalArticle

Lim, Lyndell L. ; Smith, Justine R. ; Rosenbaum, James (Jim). / Retisert Bausch & Lomb/control delivery systems. In: Current Opinion in Investigational Drugs. 2005 ; Vol. 6, No. 11. pp. 1159-1167.
@article{0d6c797ce8474840bba2815737cbf7e6,
title = "Retisert Bausch & Lomb/control delivery systems",
abstract = "Retisert (Envision TD), a sustained release intraocular implant containing fluocinolone acetonide, has been developed and launched in the US by Bausch & Lomb and Control Delivery Systems for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.",
author = "Lim, {Lyndell L.} and Smith, {Justine R.} and Rosenbaum, {James (Jim)}",
year = "2005",
month = "11",
language = "English (US)",
volume = "6",
pages = "1159--1167",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Retisert Bausch & Lomb/control delivery systems

AU - Lim, Lyndell L.

AU - Smith, Justine R.

AU - Rosenbaum, James (Jim)

PY - 2005/11

Y1 - 2005/11

N2 - Retisert (Envision TD), a sustained release intraocular implant containing fluocinolone acetonide, has been developed and launched in the US by Bausch & Lomb and Control Delivery Systems for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

AB - Retisert (Envision TD), a sustained release intraocular implant containing fluocinolone acetonide, has been developed and launched in the US by Bausch & Lomb and Control Delivery Systems for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

UR - http://www.scopus.com/inward/record.url?scp=28244456234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28244456234&partnerID=8YFLogxK

M3 - Article

C2 - 16312138

AN - SCOPUS:28244456234

VL - 6

SP - 1159

EP - 1167

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 11

ER -